These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9399983)

  • 1. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.
    Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
    Clozel M; Ramuz H; Clozel JP; Breu V; Hess P; Löffler BM; Coassolo P; Roux S
    J Pharmacol Exp Ther; 1999 Aug; 290(2):840-6. PubMed ID: 10411600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of selective endothelin receptor type A antagonist Ro 61-1790 does not improve outcome in focal cerebral ischemia in cat.
    Bhardwaj A; Wu Y; Hurn PD; Kirsch JR; Traystman RJ
    J Cereb Blood Flow Metab; 2000 Mar; 20(3):499-504. PubMed ID: 10724114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function.
    Vatter H; Konczalla J; Weidauer S; Preibisch C; Zimmermann M; Raabe A; Seifert V
    J Neurosurg; 2007 Jul; 107(1):121-7. PubMed ID: 17639881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs.
    Itoh S; Sasaki T; Ide K; Ishikawa K; Nishikibe M; Yano M
    Biochem Biophys Res Commun; 1993 Sep; 195(2):969-75. PubMed ID: 8373429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
    Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats.
    Povlsen GK; Edvinsson L
    J Cereb Blood Flow Metab; 2015 Feb; 35(2):329-37. PubMed ID: 25407271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
    Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
    Schubert GA; Schilling L; Thomé C
    J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans.
    Vuurmans JL; Boer P; Koomans HA
    Nephrol Dial Transplant; 2004 Nov; 19(11):2742-6. PubMed ID: 15328386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
    Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.